Frazier Life Sciences Management, L.P.
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Frazier Life Sciences Management, L.P. reported 49 stock positions worth $2.4 billion. Its top holding was Newamsterdam Pharma (NAMS) at 12.2% of the portfolio, followed by Krystal Biotech (KRYS, 7.4%) and Mirum Pharmaceuticals (MIRM, 6.9%). Compared with Q4 2023, it opened 7 new positions, sold out of 6, added to 13 and reduced 6. The biggest buy was Newamsterdam Pharma (NAMS, shares +1%) and the biggest sale Rhythm Pharmaceuticals (RYTM, shares −8%).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001892134
- Portfolio Value
- $2.4B (Q1 2024)
- SEC Filing
- 0001892134-24-000003 ↗ filed May 15, 2024
Holdings Value
Holdings 49 stocks · $2.4B
| NAMS Newamsterdam Pharma Co. NV | 12.23% | 12,226,943 | $289.2M | Add +0.8% |
| KRYS Krystal Biotech Inc. | 7.44% | 988,460 | $175.9M | No change |
| MIRM Mirum Pharmaceuticals Inc. | 6.90% | 6,495,392 | $163.2M | No change |
| HLVX Hillevax Inc. | 6.88% | 9,781,472 | $162.7M | No change |
| ALPN Alpine Immune Sciences Inc. | 5.25% | 3,131,008 | $124.1M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 4.54% | 10,109,279 | $107.4M | No change |
| BBIO Bridgebio Pharma Inc. | 4.47% | 3,415,604 | $105.6M | Add +25.3% |
| RYTM Rhythm Pharmaceuticals Inc. | 4.01% | 2,190,179 | $94.9M | Reduce -7.6% |
| ARQT Arcutis Biotherapeutics Inc. | 3.68% | 8,785,284 | $87.1M | Add +0.2% |
| PCVX Vaxcyte Inc. | 3.29% | 1,139,405 | $77.8M | Reduce -2.1% |
| TARS Tarsus Pharmaceuticals Inc. | 2.75% | 1,787,527 | $65.0M | No change |
| EWTX Edgewise Therapeutics Inc. | 2.55% | 3,303,567 | $60.3M | Add +23.9% |
| ORIC Oric Pharmaceuticals Inc. | 2.41% | 4,142,855 | $57.0M | Add +93.3% |
| APLS Apellis Pharmaceuticals Inc. | 2.20% | 885,165 | $52.0M | No change |
| IRON Disc Medicine Inc. | 2.07% | 785,000 | $48.9M | No change |
| VRNA Verona Pharma Ltd. | 2.05% | 3,014,349 | $48.5M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 1.85% | 3,687,867 | $43.7M | Add +1.8% |
| RCKT Rocket Pharmaceuticals Inc. | 1.78% | 1,561,230 | $42.1M | Add +2.5% |
| SLNO Soleno Therapeutics Inc. | 1.59% | 875,667 | $37.5M | Add +88.3% |
| MGNX Macrogenics Inc. | 1.54% | 2,471,704 | $36.4M | Add +2.9% |
| AEROVATE THERAPEUTICS INC | 1.51% | 1,204,867 | $35.6M | No change |
| CGON CG Oncology Inc. | 1.43% | 770,000 | $33.8M | New |
| MRUS Merus NV | 1.42% | 746,479 | $33.6M | No change |
| RVMD Revolution Medicines Inc. | 1.36% | 997,455 | $32.1M | No change |
| AUTL Autolus Therapeutics PLC | 1.25% | 4,623,324 | $29.5M | Add +23.4% |
| GPCR Structure Therapeutics Inc. | 1.14% | 629,194 | $27.0M | Add +98.4% |
| TRVI Trevi Therapeutics Inc. | 1.08% | 7,381,090 | $25.5M | No change |
| SLN Silence Therapeutics PLC-ADR | 1.05% | 1,148,591 | $24.8M | Add +30.4% |
| DCPH Deciphera Pharmaceuticals Inc. | 0.97% | 1,455,837 | $22.9M | Add +42.5% |
| PEPG Pepgen Inc. | 0.93% | 1,502,788 | $22.1M | New |
| ANAB Anaptysbio Inc. | 0.86% | 899,700 | $20.3M | No change |
| SVRA Savara Inc. | 0.84% | 4,000,000 | $19.9M | No change |
| CERE Cerevel Therapeutics Holding | 0.70% | 393,000 | $16.6M | No change |
| AGIO Agios Pharmaceuticals Inc. | 0.65% | 523,166 | $15.3M | No change |
| ADVM Adverum Biotechnologies Inc. | 0.64% | 1,069,244 | $15.1M | New |
| PBYI Puma Biotechnology Inc. | 0.63% | 2,816,294 | $14.9M | New |
| TYRA Tyra Biosciences Inc. | 0.58% | 832,220 | $13.6M | Reduce -18.9% |
| APLT Applied Therapeutics Inc. | 0.56% | 1,952,857 | $13.3M | New |
| ALLO Allogene Therapeutics Inc. | 0.54% | 2,867,750 | $12.8M | New |
| ARVN Arvinas Inc. | 0.50% | 285,331 | $11.8M | No change |
| ETNB 89BIO Inc. | 0.49% | 1,000,000 | $11.6M | Reduce -50.0% |
| ACAD Acadia Pharmaceuticals Inc. | 0.37% | 470,338 | $8.7M | Reduce -35.6% |
| COGT Cogent Biosciences Inc. | 0.27% | 936,576 | $6.3M | Reduce -53.1% |
| NTLA Intellia Therapeutics Inc. | 0.24% | 203,684 | $5.6M | No change |
| ANTX AN2 Therapeutics Inc. | 0.19% | 1,388,889 | $4.5M | No change |
| MGX Metagenomi Therapeutics Inc. | 0.12% | 279,025 | $2.9M | New |
| GRITSTONE BIO INC | 0.11% | 1,030,878 | $2.6M | No change |
| BLUEBIRD BIO INC | 0.09% | 1,709,907 | $2.2M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.01% | 264,377 | $328K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $5.5M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 500,333 | $5.5M | No change |
Total filed on the 13F, all lines: $2.4B.
Portfolio Sells Q4 2023 → Q1 2024
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -7.6% | 4.01% | −1.82 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −0.86 |
| ACAD Acadia Pharmaceuticals Inc. | Reduce -35.6% | 0.37% | −0.86 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.84 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −0.76 |
| ETNB 89BIO Inc. | Reduce -50.0% | 0.49% | −0.70 |
| PCVX Vaxcyte Inc. | Reduce -2.1% | 3.29% | −0.62 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.60 |
| THRX Theseus Pharmaceuticals Inc. | Sold out | 0.00% | −0.46 |
| COGT Cogent Biosciences Inc. | Reduce -53.1% | 0.27% | −0.36 |
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −0.25 |
| TYRA Tyra Biosciences Inc. | Reduce -18.9% | 0.58% | −0.18 |
Portfolio Buys Q4 2023 → Q1 2024
| NAMS Newamsterdam Pharma Co. NV | Add +0.8% | 12.23% | +4.98 |
| ARQT Arcutis Biotherapeutics Inc. | Add +0.2% | 3.68% | +2.17 |
| CGON CG Oncology Inc. | New | 1.43% | +1.43 |
| ORIC Oric Pharmaceuticals Inc. | Add +93.3% | 2.41% | +1.35 |
| EWTX Edgewise Therapeutics Inc. | Add +23.9% | 2.55% | +0.99 |
| PEPG Pepgen Inc. | New | 0.93% | +0.93 |
| ADVM Adverum Biotechnologies Inc. | New | 0.64% | +0.64 |
| PBYI Puma Biotechnology Inc. | New | 0.63% | +0.63 |
| SLNO Soleno Therapeutics Inc. | Add +88.3% | 1.59% | +0.58 |
| APLT Applied Therapeutics Inc. | New | 0.56% | +0.56 |
| ALLO Allogene Therapeutics Inc. | New | 0.54% | +0.54 |
| GPCR Structure Therapeutics Inc. | Add +98.4% | 1.14% | +0.45 |
| MGNX Macrogenics Inc. | Add +2.9% | 1.54% | +0.30 |
| SLN Silence Therapeutics PLC-ADR | Add +30.4% | 1.05% | +0.23 |
| MGX Metagenomi Therapeutics Inc. | New | 0.12% | +0.12 |
| DCPH Deciphera Pharmaceuticals Inc. | Add +42.5% | 0.97% | +0.09 |
| AUTL Autolus Therapeutics PLC | Add +23.4% | 1.25% | −0.04 |
| KALV Kalvista Pharmaceuticals Inc. | Add +1.8% | 1.85% | −0.52 |
| RCKT Rocket Pharmaceuticals Inc. | Add +2.5% | 1.78% | −0.66 |
| BBIO Bridgebio Pharma Inc. | Add +25.3% | 4.47% | −1.42 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 40 | $4.6B | MIRM, NAMS, ERAS, MBX, ARQT |
| Q1 2026 | 37 | $3.9B | MIRM, NAMS, ERAS, BBIO, ARQT |
| Q4 2025 | 39 | $3.7B | NAMS, MIRM, ARQT, BBIO, MBX |
| Q3 2025 | 46 | $3.3B | MIRM, NAMS, VRNA, BBIO, ARQT |
| Q2 2025 | 48 | $2.5B | MIRM, VRNA, NAMS, BBIO, ARQT |
| Q1 2025 | 46 | $2.2B | NAMS, MIRM, VRNA, ARQT, BBIO |
| Q4 2024 | 49 | $2.4B | NAMS, MIRM, VRNA, KRYS, ARQT |
| Q3 2024 | 52 | $2.5B | MIRM, NAMS, PHAT, KRYS, MBX |
| Q2 2024 | 48 | $2.1B | NAMS, MIRM, KRYS, HLVX, PHAT |
| Q1 2024 | 49 | $2.4B | NAMS, KRYS, MIRM, HLVX, ALPN |